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Abstract We propose a normalization of symbols and terms
used to describe, accurately and succinctly, the detailed
interactions between amino acid residues of pairs of interacting
proteins at protein:protein (or protein:peptide) interfaces. Our
aim is to unify several diverse descriptions currently in use in
order to facilitate communication in the rapidly progressing field
of signaling by protein domains. In order for the nomenclature
to be convenient and widely used, we also suggest a parallel set
of symbols restricted to the ASCII format allowing accurate
parsing of the nomenclature to a computer-readable form.
This proposal will be reviewed in the future and will therefore
be open for the inclusion of new rules, modifications and
changes. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
At the recent conference on ‘Functional Protein Modules’1
we discussed the urgent need of a uni¢ed glossary for describ-
ing protein^protein interactions of small, functional domains
with their peptide ligands. We propose a formalization of
terms to enable the detailed description of residues involved
in the protein:ligand interaction interface. This includes sep-
arate notations for (i) the consensus sequences of the cognate
peptide ligands recognized by protein modules and (ii) the
‘epitopes’ (sometimes discontinuous) of the modules them-
selves, which interact directly with the ligand. This e¡ort is
aimed at unifying several diverse descriptions currently in use
in the scienti¢c literature, in order to facilitate communication
in the rapidly developing ¢elds of signal transduction and
proteomics.
2. De¢nitions: modular protein domains and their peptide
ligands
Modular protein domains (also known as protein modules
or protein^protein interaction domains) are well demarcated
and independently folded portions of proteins typically com-
prising 40^200 amino acids [1^3]. These domains are non-cat-
alytic and bind speci¢cally to short continuous peptide se-
quences in their binding partner(s) via one or more exposed,
ligand-binding surfaces (‘ligand recognition pockets’). They
are described as modular because of their frequent occurrence
in various proteins and/or the fact that they often occur in
multiple repeats within a single protein. They are autonomous
in the sense that in most cases they may be removed from the
original parent protein without compromising their ability to
bind their cognate or target peptide ligands. The domain^li-
gand interactions are reversible and generally of low a⁄nity
(Kd values typically between 1 and 500 WM). Complementary
‘epitopes’ present in both the domain and its target ligand act
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together to encode speci¢city and a⁄nity in a co-operative
manner.
In general, a number of highly conserved residues in the
domain make direct contacts to the amino acids of the ligand.
In cases where the presence of a ligand induces folding of part
of a domain, the directly interacting ‘contact’ residues are also
important for maintaining the structure of the complex.
Ligands interact with their complementary domains
through short and generally continuous sequence motifs (the
core motifs), composed of three to six amino acids (Fig. 1). In
some cases certain amino acids of the ligands must be post-
translationally modi¢ed before recognition and binding can
occur (e.g. phosphorylation or acetylation for ligands of
SH2 and bromo domains, respectively). In other cases post-
translational modi¢cation of target sequences downregulates
binding by preventing interactions, usually sterically or via
charge repulsion (e.g. phosphorylation or methylation of the
ligands of certain WW and SH3 domains).
3. Rules for peptide ligands and protein domains
The following rules propose a general syntax for the repre-
sentation of consensus sequences and conserved residues when
describing complementary binding ‘epitopes’ involved in pro-
tein:peptide interactions. Single-character strings would thus
be generated using speci¢c symbols for di¡erent subsets of
amino acids, de¢ned on the basis of their chemical properties,
including, where relevant, status of post-translational modi¢-
cation.
1. Continuous peptide ligands are represented by a linear
string of amino acids in single-character notation as de-
scribed by The International Union of Pure and Applied
Chemistry (IUPAC) and International Union of Biochem-
istry and Molecular Biology (IUBMB) [4]. All letters sym-
bolizing amino acids are capital. Lower-case letter ‘x’ is
proposed to denote ‘unknown, other or any amino acid’.
2. Unless stated otherwise, for speci¢c reasons, the default ‘0’
(zero) position should be assigned to the most ‘important’
amino acid within the ligand core and the remaining amino
acids are designated ‘31’, ‘32’, and ‘1’, ‘2’, toward the (N-)
amino- and (C-) carboxy-terminal directions, respectively
(Fig. 1). Where there are multiple ‘important’ or critical
residues (e.g. PxxP core of SH3 ligands), the most N-ter-
minal of them should be designated ‘0’. In cases where
structures of complexes are not available and mutational
analysis of ligands is missing, an initial assignment would
be arbitrary.
3. With two or three known exceptions where the free car-
boxy-terminal end is an integral part of the ligand (e.g.
ligands of PDZ domains), the core motifs are surrounded
by £anking amino acids at their amino- and carboxy-ter-
mini, whose sequences are not given in detail but are rep-
resented by general symbols ‘fn’ or ‘fc’ respectively (Fig. 1).
Absence of fn or fc in notation would indicate that the
N- or C-terminal residue of the core motif is the respective
terminus. Flanking sequences in concert with core motifs
dictate the speci¢city of interaction within a given family of
modules and are an important part of ligand characteriza-
tion. Whenever possible they should be speci¢ed as direct
and/or consensus sequences before and after fn and fc sym-
bols.
4. Hydrophobic amino acids are represented by ‘x’ (Phi) be-
cause of phonetic relation between ‘phi’ and ‘phobic’. The
following amino acids are considered hydrophobic: V, I, L,
F, W, Y and M.
5. Aromatic amino acids are represented by ‘6’ (Omega) and
they include F, W, Y. The letter 6 is derived from the
Greek word 6bKSY, pronounced Oreo, meaning pleasant,
and frequently used to describe aroma. The visual mne-
monic here is the round shape of ‘Oreo’ cookie that is
reminiscent of the closed aromatic ring.
6. Hydrophilic amino acids are represented by lower-case (not
capital) ‘j’ (zeta). The letter is derived from the Greek
word jgR, pronounced zoi, which means life, a simile to
water (hydro). N, Q, S and T are hydrophilic uncharged
amino acids and hydrophilic charged amino acids are:
E, D, K, R and H.
7. Amino acids with large aliphatic side chains have been
traditionally marked with, and should continue to be des-
ignated, ‘8’ (Psi) ; again because of the phonetic similarity
between ‘aliphatic side’ and ‘psi’. Side chains of V, I, L and
M belong to this group. (Annotations are recommended
whenever symbols for groups of amino acids described in
rules 4^7 are used.)
8. Charged residues will be marked with [+] (positive) and [3]
(negative), the square brackets to be included in the nota-
tion. Direct speci¢cation of amino acids is recommended
where appropriate. For example, for a position occupied
by negatively charged amino acids the alternative choice
would be (E/D).
9. Amino acids with small chains, namely P, G, A and S, will
be named with letter Z (pi) after representative proline.
10. Phosphorylated amino acids are indicated by lower-case
‘po’ in italics without a dash connecting it to the modi¢ed
amino acid, e.g. poY is phospho-tyrosine (Fig. 1). Italics
are suggested for symbols of post-translational modi¢ca-
tion because in certain conventions lower-case symbols
for certain amino acids are used for highly but not com-
pletely conserved positions. For symbols of other post-
synthetic modi¢cations, not indicated in this glossary, re-
fer to examples listed in the supplement to reference [5].
11. Sulfated amino acid, namely tyrosine, is indicated by ‘su’
^ suY.
12. O-Glycosylated serine and threonine on hydroxyl groups
by a single L-N-acetylglycosamine have been identi¢ed
Fig. 1. Formalization of terms to describe protein^protein interac-
tions mediated by modules and their cognate peptide ligands using
the SH2 domain and its ligand as example.
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and characterized in cytoplasmic and nuclear proteins.
Past abbreviations were S-(O-GlcNAc) or T-(O-GlcNAc).
We suggest to use glS and glT symbols. N-Glycosylated
amino acids should also be indicated with the gl pre¢x
(e.g. glN may indicate glycosylated asparagine).
13. Methylated amino acids will be indicated by ‘me’ in italics
whether it is mono- or dimethyl- form (e.g. mono- or
dimethyl-arginine will be: meR). Since symmetrical and
asymmetrical methylations have been shown to modulate
protein^protein interaction di¡erentially, we suggest ‘sme’
for symmetrical and ‘ame’ for asymmetrical methylation
(e.g. symmetrically dimethylated arginine will be indicated
by smeR, whereas the asymmetrically dimethylated var-
iant will be marked by ameR).
14. Acetylated amino acids will be indicated with ‘ac’ in
italics (e.g. acetyl-lysine will be: acK).
15. Hydroxylated proline will be indicated by hyP.
16. Amino acids to be excluded from a given position in a
consensus motif should be marked by ‘^’ (e.g. ^P ^ no
proline at this position allowed, or ^(R/K/W) ^ no argi-
nine or lysine or tryptophan allowed).
17. For ¢gures, tables and graphical representations of do-
main^ligand complexes, the residues of the ligand, which
pack closely into the domain surface, are underlined with
yellow boxes or marked with yellow background (Fig. 1).
18. Variations in primary and ultimately in tertiary structures
of domains contribute to the speci¢city of interaction with
the ligand. A term, ‘epsilon determinant(s)’ (O, from the
Greek word for speci¢city: OSNSUYdRdK, pronounced ede-
kohteta), was proposed for those amino acids within do-
mains which determine ligand predilections [6]. The O de-
terminant is represented by one or several amino acid
positions located mainly within the conserved structure
of the domain, and usually in the ligand-binding interface.
Notation for O determinants was previously described:
(Substructure Letter Number) [6^8]. To illustrate it by ex-
ample: The O determinant for one of the classes of SH2
domains was represented by the LD5 position (the nota-
tion indicated ¢fth amino acid in the fourth L-strand; D
indicated the fourth) and occupied by aromatic residues,
tyrosine or phenylalanine. To avoid any confusion with
one-letter symbols of amino acids, we propose to change
this notation by replacing non-Greek letters referring to
the order of secondary structural element with numbers.
Previously the O determinant for class I of SH2 domains
was LD5 = (Y/F). We propose to use: L4-5 = (Y/F). For
another class of SH2 domains, the O determinant resides
in the EF1 position (the ¢rst amino acid position in the
loop between E [¢fth] and F [sixth] L-strands). We pro-
pose 5:6-1 notation; a loop would be indicated by ‘:’. For
more details see [6^8].
4. Alternative nomenclature in ASCII format
Considering the rapid progress in ¢elds of molecular signal-
ing and proteomics, we have also identi¢ed a need for a par-
allel set of symbols in ASCII format, i.e. a complete set of
symbols found on any standard computer keyboard. In Table
1 we summarize all terms in non-ASCII style ^ the terms
described above in 18 rules, and their equivalents in ASCII
format.
5. Three examples of nomenclature in both formats
1. Tyrosine phosphorylated motif: fnAGpoY(G/A/P/S)HFfc
or fnAGpoYZHFfc ; and in ASCII format: fnAG[Y:po]-
(G/A/P/S)HFfc or fnAG[Y:po]VHFfc. Note that when
several amino acids are allowed at a certain position,
they are placed in parentheses and separated by slashes.
2. A peptide core terminating with methylated (or carboxy-
methylated) leucine: fnPALPPAmeL; and in ASCII for-
mat: fnPALPPA[L:me].
3. One of the O determinants for class II WW domains is LB6
position occupied by aromatic amino acids: L2-6 =6 ; in
ASCII format: (beta2)6 = @.
6. Concluding remarks
Our proposal is open for the inclusion of new rules, mod-
i¢cations and changes, and we hope to update this nomencla-
ture again at the next international gathering of researchers in
the ¢eld of protein modules. Several principles guided us in
compiling this glossary: (i) previous and/or prevalent symbols
should be primary choices and if needed only minimally modi-
¢ed [1,5^8]; (ii) the phrases to describe consensus sequences
should be as simple as possible while being unequivocal;
(iii) symbols for post-translational modi¢cations and other
annotations should be set in lower-case characters and placed
in front of the modi¢ed amino acid residue. For ASCII for-
mat we place modi¢cations after the modi¢ed amino acid,
with ‘ :’ in between, and close the composite symbol in brack-
ets, following recommendations of Bader et al. [5].
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Table 1
Summary of symbols for representing consensus sequences of pep-
tide ligands and protein modules
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